CLASS ACTION UPDATE for EBS, VRUS and CCXI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
EBS Shareholders Click Here: https://www.zlk.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=15578&wire=1
VRUS Shareholders Click Here: https://www.zlk.com/pslra-1/verus-international-inc-loss-submission-form?prid=15578&wire=1
CCXI Shareholders Click Here: https://www.zlk.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=15578&wire=1
* ADDITIONAL INFORMATION BELOW *
Emergent Biosolutions Inc. (NYSE:EBS)
EBS Lawsuit on behalf of: investors who purchased July 6, 2020 - March 31, 2021
Lead Plaintiff Deadline : June 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=15578&wire=1
According to the filed complaint, during the class period, Emergent Biosolutions Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.
Verus International, Inc. (OTC PINK:VRUS)
VRUS Lawsuit on behalf of: investors who purchased June 17, 2019 - November 8, 2020
Lead Plaintiff Deadline : June 22, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/verus-international-inc-loss-submission-form?prid=15578&wire=1
According to the filed complaint, during the class period, Verus International, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Verus lacked the requisite resources, infrastructure and/or expertise to exploit its Big League Foods brand and its MLB license; (ii) the company's issues in production ramp-up were not fully resolved to enable the company to fulfill customer orders; (iii) as a result, the company's prospects and outlook were not as represented; (iv) the company's internal controls for financial reporting and accounting were not sufficient with specific respect to stock-based compensation and classification of equity instruments; (v) as a result, the company's financial results, outlook and prospects were materially worse than represented; and (vi) as a result of the foregoing, the company's public statements were materially false and misleading at all relevant times.
ChemoCentryx, Inc. (NASDAQ:CCXI)
CCXI Lawsuit on behalf of: investors who purchased November 26, 2019 - May 3, 2021
Lead Plaintiff Deadline : July 6, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=15578&wire=1
According to the filed complaint, during the class period, ChemoCentryx, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's NDA for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/645561/CLASS-ACTION-UPDATE-for-EBS-VRUS-and-CCXI-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
